ALG-097558
COVID-19
PreclinicalStatus Unclear (Deprioritized)
Key Facts
About Aligos Therapeutics
Aligos Therapeutics is a clinical-stage biotech focused on developing best-in-class therapies for chronic liver and viral diseases, specifically chronic hepatitis B (CHB) and MASH. The company employs a targeted, chemistry-driven approach to design small molecules with optimized pharmacological profiles. Its strategy centers on a lean, experienced team with a proven track record in hepatology and virology drug development, aiming to advance a focused pipeline through key clinical milestones. Despite a challenging financial position with a low market valuation, its progress is defined by upcoming Phase 2 data for its lead assets.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |